NCT04815967View on ClinicalTrials.gov

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity

PHASE2/PHASE3UnknownINTERVENTIONAL

Enrollment

272

Participants

Timeline

Start Date

November 16, 2021

Primary Completion Date

July 1, 2023

Study Completion Date

July 1, 2024

Conditions

SpasticityCerebrovascular AccidentMultiple SclerosisTraumatic Brain InjuryCervical Spinal Cord InjuryCerebral Palsy

Interventions

DRUG

Phase 2; Low Dose MYOBLOC

Intramuscular injections on Day 1

DRUG

Phase 2; High Dose MYOBLOC

Intramuscular injections on Day 1

DRUG

Phase 2; Placebo

Intramuscular injections on Day 1

DRUG

Phase 3; MYOBLOC

Intramuscular injections on Day 1

DRUG

Phase 3; Placebo

Intramuscular injections on Day 1

Trial Locations (9)

29935

Coastal Neurology, Port Royal

34209

Nova Clinical Research, LLC, Bradenton

37232

Vanderbilt University Medical Center, Nashville

75390

University of Texas Southwestern Medical Center, Dallas

83706

Idaho Physical Medicine and Rehabilitation, Boise

90242

Rancho Research Institute, Downey

06905

New England Institute for Clinical Research, Stamford

Unknown

Fakultní nemocnice Brno, Neurologická klinika FN Brno (University Hospital Brno, Department of Neurology), Brno

Centrum pro intervenční terapii motorických poruch, Neurologická klinika, Univerzita Karlova Katerinska, Prague

Sponsors

Collaborators (1)

Solstice Neurosciences

All Listed Sponsors

collaborator

Solstice Neurosciences

INDUSTRY

lead

Supernus Pharmaceuticals, Inc.

INDUSTRY